Up a level |
Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo HM, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit et al (show 5 more authors)
(2019)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.
Circulation, 139 (17).
pp. 2022-2031.
Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P, Cahn, Avivit, Kato, Eri T, Silverman, Michael G, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404 et al (show 5 more authors)
(2018)
DECLARE-TIMI 58: Participants' baseline characteristics.
DIABETES OBESITY & METABOLISM, 20 (5).
pp. 1102-1110.
Bonaca, Marc P, Wiviott, Stephen D, Zelniker, Thomas A, Mosenzon, Ofri, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Goodrich, Erica L, De Mendonca Furtado, Remo Holanda, Wilding, John PH ORCID: 0000-0003-2839-8404 et al (show 8 more authors)
(2020)
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Circulation, 142 (8).
pp. 734-747.
Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A et al (show 13 more authors)
(2019)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
CIRCULATION, 139 (22).
pp. 2528-2536.
Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM et al (show 5 more authors)
(2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
LANCET, 393 (10166).
pp. 31-39.
Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A et al (show 6 more authors)
(2018)
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
AMERICAN HEART JOURNAL, 200.
pp. 83-89.